Loading…
Mettler-Toledo International Inc.
S&P 500
🏹 Trader: ⭐ All Three 🚀 Stage 2 + Near High 📈 Stage 2 🎯 Near 52W High 📊 High Volume | BRS 83 Ready View all →
📈 Stage 2 detected Find the fundamental catalyst → → run Growth Triggers in Ask AI
$29.3B
Market Cap
33.2
P/E
3.23
PEG
40.4%
ROCE
N/M
ROE
-91.05
D/E
27.8%
OPM
-7.1%
% from 52W High
67
α RS
🔍 MTD is showing a high-conviction setup because it matches 9 of 37 tracked screener presets, Sector RRG has Health Care in the Leading quadrant with the trail still rolling over, and RS Rating is 67. Net: Broad signal stack, not a recommendation. ? Conviction RRG RS Rating
Sources
Conviction 9/37 · Health Care in Leading quadrant · RS Rating 67
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides
🌏 Global Investor Returns
Currency-adjusted total returns for MTD including FX impact
🌏
Click 🌏 Returns tab to load data
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
📊 Sector Averages
About

Mettler-Toledo International Inc. manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally.

Key Ratios Snapshot
📈 Growth Pattern
📊 Quick Scorecard
Loading…
⭐ Superinvestors Holding MTD
View All Superinvestors →
Manager Shares Value % of Fund Period
Steve Cohen Point72 Asset Management 28.8K $36.3M 0.05% Mar 2026
Jim Simons Renaissance Technologies LLC 8.4K $10.5M 0.02% Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
🎙 Management Tone Confident Specific ~ Volatile 5 quarters Full tone analysis in Intelligence →
Good quarter Investor Presentation One-Pager? Q2 2026
Revenue
$1.027B
+4% YoY reported; +6% LC ex-tariff refunds; +4% organic
Adjusted Operating Profit
$309M
+9% YoY
Adjusted Operating Margin
29.3%
+50bps YoY; +100bps ex-FX
Adjusted EPS
$11.46
+14% YoY
What Went Right
  • Local-currency sales grew 6% (organic +4%), beating the ~3% guidance.
  • China returned to 9% organic growth, and emerging markets ex-China grew high single digits (≈18% of sales).
  • Adjusted EPS rose 14% to $11.46; FY adjusted EPS guidance midpoint raised by ~$0.70 to ~$47.33.
What to Watch
  • Q3 comparisons are tough: Americas lapped +9% organic and Core Industrial +10% organic in the year-ago quarter; Q3 LC sales guided to only +4%.
  • Middle East volatility is not in the forecast; an escalation could dampen customer decision-making.
  • FX is a ~1% EPS headwind in Q3, transportation costs pressured gross margin, and Product Inspection grew just 1% on project timing.
Management Guidance
  • Q3 2026: local-currency sales +~4% (incl. ~0.5pts acquisitions); adjusted EPS $12.00-$12.15 (+8-9%; +9-10% ex-FX).
  • FY 2026: local-currency sales +~4-5% (organic +3-4%), raised from ~4%; adjusted EPS $47.15-$47.50 (+10-11%; +11-12% ex-FX), raised from $46.30-$46.95.
  • FY 2026 FCF guided to ~$900M; share repurchases increased to ~$875M from the $825M H1 annualized rate.
Investor Lens
The thesis is stronger after this call — Q2 beat on both growth and margin, China/EM momentum improved, and management raised the full-year EPS outlook. Pricing held ~3% and productivity translated into 100bps ex-FX operating margin expansion, reinforcing the franchise's earnings power. The offset is that H2 guidance still implies slower growth on difficult comps and management left Middle East risk unmodelled. Overall, the risk/reward is positive if industrial replacement demand and reshoring continue to build.
From investor presentation · AI-generated analysis · Not investment advice
🔒
Premium Feature
Investor Presentation One-Pager — quarterly highlights, what went right/wrong & management guidance
Upgrade to Premium
Already a member? Log in
📈 STRONG Q2 beat: LC sales +6%, adjusted EPS +14%, guidance raised.
Revenue
Q2 reported sales were $1.027B, up 4% YoY; excluding the one-time $28M customer tariff refund, local-currency sales grew 6% (organic +4%), ahead of ~3% guidance. Organic growth was 1% in the Americas, 4% in Europe and 9% in Asia/RoW, with China at +9%. By division, Lab +4%, Industrial +3% (Core Industrial +4%, Product Inspection +1%), Food Retail +11%, and services +9% (7% organic).
Profitability
Adjusted operating profit increased 9% to $309M, and adjusted EPS rose 14% to $11.46. Reported EPS was $11.55 versus $9.76, including a $0.92 net tariff-refund benefit, $0.26 amortization, $0.22 restructuring, a $0.04 tax headwind and a $0.31 acquisition-related charge.
Margins
Adjusted gross margin expanded 30bps to 59.3%, or ~90bps excluding FX and acquisitions, helped by ~3% price realization, lower tariffs and productivity, but partly offset by higher transportation costs. Adjusted operating margin was 29.3%, +50bps YoY (+100bps ex-FX).
Balance Sheet
Year-to-date adjusted free cash flow was $367M, negatively impacted by $55M higher tax payments; FY 2026 FCF is guided to ~$900M. DSO was 35.6 days and ITO 4.2x. Share repurchases are expected to rise to ~$875M for the year.
Key Risks
Management flagged Middle East volatility as not included in the forecast and noted FX is a ~1% EPS headwind in Q3. Q3 faces difficult comps — Americas and Core Industrial both grew ~9-10% organic in the year-ago quarter — and Product Inspection's Q2 growth was only 1% due to project timing. Chemical end-markets in Europe recovered in Q2, but management remains cautious on energy-cost exposure.
Outlook
Q3 2026 guidance: local-currency sales +~4% (incl. ~0.5pt M&A) and adjusted EPS of $12.00-$12.15 (+8-9%, or +9-10% ex-FX). FY 2026 guidance was raised to LC sales +~4-5% (organic +3-4%) and adjusted EPS of $47.15-$47.50 (+10-11%, or +11-12% ex-FX) from the prior $46.30-$46.95.
Generated by AI · Q2 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter
🔍
🔎 See cross-company document search → ?
📞 Earnings Call Transcripts (5)
Q2 2026 Q2 2026 2026-07-31
Q2 saw strong organic sales and EPS growth, led by China and emerging markets, with margin expansion and robust performance in Lab and Industrial segments. Full-year guidance was raised for sales and EPS, with continued focus on automation, digitalization, and emerging market growth.
Q1 2026 Q1 2026 2026-05-08
Delivered strong Q1 results with 9% adjusted EPS growth and robust performance in industrial automation and bioprocessing, offset by softness in Western markets and chemical sectors. Full-year guidance raised for adjusted EPS, with continued focus on innovation and margin expansion.
Q4 2025 Q4 2025 2026-02-06
Q4 and full-year 2025 saw strong sales and EPS growth, with robust performance across segments and geographies despite tariff and currency headwinds. 2026 guidance calls for continued sales and EPS growth, with innovation and service expansion as key drivers.
Q3 2025 Q3 2025 2025-11-07
Q3 2025 saw strong growth in Industrial and solid EPS, with robust execution amid global uncertainties. Guidance for 2026 anticipates 4% sales growth and 8–9% EPS growth, with tariff headwinds expected to be fully offset. Innovation, automation, and targeted acquisitions support future momentum.
Q2 2025 Q2 2025 2025-08-01
Q2 2025 saw solid adjusted EPS growth and resilient performance across most segments, despite tariff headwinds and challenging market conditions. Full-year EPS guidance was revised down by $0.40 due to new U.S. tariffs on Swiss imports, with mitigation actions underway and full offset expected by 2026.
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, ECS update, earnings-call, and SEC announcement for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

Financial Model
Projections are built from each company's audited annual financials (Income Statement, Balance Sheet, Cash Flow) over the last 5 fiscal years. Forward assumptions — revenue growth %, EBITDA margin, D&A (USD millions), interest expense, tax rate, and capex — are AI-generated using historical context and refreshed twice a year: after the December results season and after the September/Q4 results season.

DCF Valuation
Fair Value = Σ(FCFt / (1+WACC)t) + Terminal Value. Terminal Value uses the Gordon Growth Model: FCF5 × (1+g) / (WACC−g). Default WACC: 10% (US risk-free ~4.5%, equity risk premium ~5.5%). Default terminal growth: 3% (long-run US nominal GDP proxy).

CAGR Tracker
Expected 5-year CAGR = (DCF Fair Value / Current Price)1/5 − 1. Assumes fair value is reached in exactly 5 years — a mechanical estimate only.

Data Sources & Limitations
Financial statements sourced from public filings. Prices updated daily. Forward assumptions are AI-generated. All monetary values in USD millions. Non-US ADR companies may have currency conversion inaccuracies. Models are point-in-time and do not update intra-quarter or account for M&A, macro shocks, or extraordinary items.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.